13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001953107
Total reported value
$345.4M
$345.4M
6 檔
34.1%
As reported in its official Q1 2025 Form 13F filing, Enavate Sciences GP, LLC's tracked investment portfolio stood at $345.4M with 6 total positions.
During Q1 2025, Enavate Sciences GP, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IMNM | Immunome Inc | Stock-Other | 24.18% | -0.31% | +37.10% | |
| 2 | ZBIO | Zenas Biopharma Inc | Stock-Other | 22.39% | +7.00% | — | |
| 3 | SION | Sionna Therapeutics Inc | Stock-Other | 19.53% | +3.30% | — | |
| 4 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 11.41% | -0.95% | — | |
| 5 | UPB | Upstream Bio Inc | Stock-Other | 11.34% | -1.37% | — | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 11.15% | -6.78% | — |
According to official SEC Form 13F filings, Enavate Sciences GP, LLC reported a total U.S. public equity portfolio value of $345.4M across 6 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IMNM, ZBIO, SION) accounted for 34.1% of total reported equity market value during Q1 2025.
During Q1 2025, Enavate Sciences GP, LLC's top holdings by market value included IMNM (24.2%)、ZBIO (22.4%)、SION (19.5%). The largest single position, IMNM, represented 24.2% of total portfolio value.
In Q1 2025, Enavate Sciences GP, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.